AI Article Synopsis
- A study aimed to identify risk factors for metachronous peritoneal metastases (PM) in stage II or III colon cancer after treatment, using data from the California Cancer Registry from 2004 to 2012.
- Factors associated with increased risk of PM recurrence included being female, having a T4 primary tumor, certain histological types like mucinous or signet-ring, and right-sided colon cancer.
- Patients with PM recurrence had a significantly lower median survival (12 months) compared to those without it (22 months), highlighting the need for better understanding of tumor characteristics for potential targeted therapies.
Article Abstract
Background: A subset of metachronous colon cancer recurrence manifests as peritoneal metastases (PM). Risk factors for metachronous PM recurrence are not well-defined in patients with stage II or III colon cancers after curative resection and standard adjuvant treatments.
Methods: Population data from the California Cancer Registry for patients with Stage II or III colon cancer were collected between 2004 and 2012. Multivariate analysis was used to identify factors associated with metachronous PM.
Results: Of the 2077 patients with stage II or III colon cancer, female patients (odds ratio [OR] = 1.84, p = 0.02), T4 primary tumor (OR = 2.36, p = 0.02), mucinous (OR = 3.97, p < 0.01) or signet-ring histology (OR = 6.01, p = 0.01), and right-sided cancer (OR = 2.2, p < 0.01) were found with increased risk of metachronous isolated PM recurrence after curative resection. Median survival after diagnosis for patients without PM recurrence was 22 months, compared with 12 months for PM recurrence (p < 0.001).
Conclusion: PM recurrence groups have a worse overall survival than patients with recurrent disease in other sites. A better understanding of the tumor biology and molecular characteristics of colon cancers likely to recur as PM is needed to explain behavior and identify potential targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.26322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway.
Biochim Biophys Acta Mol Basis Dis
January 2025
Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou City, Guangdong Province 510280, China. Electronic address:
Background: Oxaliplatin is the first-line chemotherapy for patients with colon cancer (CC). However, its resistance limits its therapeutic efficacy.
Methods: Oxaliplatin resistance-associated differentially expressed genes (DEGs) in the GSE42387 and GSE227315 datasets were identified through bioinformatics methods.
Polysaccharides from maggot extracts suppress colorectal cancer progression by inducing ferroptosis via HMOX1/GPX4 signaling pathway.
Int J Biol Macromol
January 2025
the Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing 210009, China; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, 42 Baiziting Road, Xuanwu District, Nanjing 210009, China. Electronic address:
Maggots contain various kinds of polysaccharides and recent studies mostly concentrated on their anti-inflammatory functions. While the molecule mechanisms related to the polysaccharides inhibiting carcinogenesis remains unclear. Here we characterized the polysaccharides extracted from maggot (MEs) determining their anti-colon cancer potentials.
View Article and Find Full Text PDFPolysaccharide-based drug delivery targeted approach for colon cancer treatment: A comprehensive review.
Int J Biol Macromol
January 2025
Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address:
Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.
View Article and Find Full Text PDFImpact of Chemotherapy Treatment on the Functionality and Quality of Life of Cancer Patients.
Physiother Res Int
January 2025
Universidade do Oeste de Santa Catarina, Joaçaba, Brasil.
Background And Purpose: Cancer is one of the most prevalent diseases in the general population, and is one of the main causes of changes in the population's illness profile. In this study, we assessed changes in the functional status and quality of life of patients in the first months of chemotherapy treatment.
Method: A prospective cohort study was carried out, collecting data from cancer patients seen at an outpatient clinic in the Midwest of Santa Catarina who had breast, lung, colon and rectum, prostate and head and neck cancer.
'Pseudokidney' And 'Donut' signs of Colon cancer on Point-of-Care Ultrasound.
QJM
January 2025
Gastroenterology Unit, Department of Medicine, RIPAS Hospital, Jalan Putera Al-Muhtadee Billah, Bandar Seri Begawan, BA1712, Brunei Darussalam.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!